• study
  • The study was limited because the remission rate was lower than expected, which reduced its statistical power, and also because follow-up was too short to determine if there were any differences in longer-term effects of each induction agent on relapses. (medpagetoday.com)
  • The purpose of this study is to evaluate the efficacy and safety of daratumumab plus cyclophosphamide, bortezomib and dexamethasone. (evidence.nhs.uk)